The Board of Directors of BOIRON, at its meeting of March 19, 2014 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31, 2013. It was decided to call a Combined Shareholders Meeting on May 22, 2014 at the company's headquarters in Messimy.
Audits of the statutory and consolidated financial statements have been performed and the audit reports concerning their certification are currently in the process of being issued.
BOIRON GROUP RESULTS
in thousands of euros
2012
Published
2012
Restated (1)
2013
Variation
2013/2012
Restated
Sales
566,294
566,294
617,731
+9.1%
Operating income
81,109
85,584
134,306
+56.9%
Net Income - Group share
49,626
50,296
82,396
+63.8%
Cash Flow
114,736
114,736
164,310
+43.2%
Tangible and intangible net gross investments
19,135
19,135
24,236
+26.7%
Net cash position
94,704
94,704
159,775
+68.7%
(1) Following application of the revised IAS 19 norm relating to post-employment social commitments.
Profitability improved significantly through:
the increase of sales, in particular due to the high pathology in the first quarter,
the control of operating costs,
costs savings generated by the recent reorganizations in Italy, Belgium and Switzerland.
Operating income was however impacted by the reorganization costs in Spain and Belgium up to €7,066 thousand.
The Board of Directors will propose to the Combined Shareholders Meeting the distribution of a dividend of €1.20 per share. The payment of the dividend will be June 6, 2014.
Following the exceptional year 2013 which was in particular marked by a high pathology, the group is cautious regarding its 2014 outlook.
Our next update:
April 24, 2014, at market close, publication of quarterly sales and financial information as of March 31, 2014.
Person responsible for financial information: Philippe Montant
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0)4.78.45.63.43 - E-mail: finances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at : www.boiron.com
Information réglementée Communiqués au titre de l′obligation d′information permanente :
- Communiqué sur comptes, résultats, chiffres d′affaires
Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-35167-cp-boiron_190314.pdf
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).